Appeals court blocks mailing of abortion pill mifepristone in U.S.
A federal appeals court has blocked the mailing of the abortion pill mifepristone, requiring it to be distributed in person at clinics. The ruling stems from a challenge by Louisiana, which argues that mail access undermines its state abortion ban. The decision may lead to a Supreme Court appeal, as advocates warn it threatens access to medication abortion, especially in restricted states.
- ▪The 5th U.S. Circuit Court of Appeals ruled that mifepristone must be distributed in person, not by mail.
- ▪Louisiana's law considers an unborn child a legal person from conception, and state officials argue mail access violates this policy.
- ▪Mifepristone was approved in 2000 and has been safely used for over two decades, with FDA oversight confirming its safety.
- ▪The FDA is currently reviewing mifepristone's safety under direction from President Trump, but has not completed the review.
- ▪Advocacy groups argue the ruling endangers access for rural populations, survivors of domestic violence, and people with disabilities.
Opening excerpt (first ~120 words) tap to expand
U.S. Appeals court blocks mailing of abortion pill mifepristone in U.S. May 1, 2026 / 7:24 PM EDT / CBS/AP Add CBS News on Google A federal appeals court on Friday restricted access to one of the most common means of abortion in the U.S. by blocking mailing of prescriptions of mifepristone.A panel of the New Orleans-based 5th U.S. Circuit Court of Appeals is requiring that the abortion pill be distributed only in person at clinics."Every abortion facilitated by FDA's action cancels Louisiana's ban on medical abortions and undermines its policy that 'every unborn child is human being from the moment of conception and is, therefore, a legal person,'" the ruling states.In their ruling, the judges stated that the current regulation "creates an effective way for an out-of-state prescriber to…
Excerpt limited to ~120 words for fair-use compliance. The full article is at CBS News — Top.
Discussion
0 commentsMore from CBS News — Top
